RECOVER™ Digital Newsroom

Please use the buttons next to the thumbnails to preview or download the video clips

Results and implications of the RE-COVER^™ study

		Results and implications of the RE-COVER^™ study

		Venous thromboembolism - a real challenge

		Venous thromboembolism and deficits in oral anticoagulation

		The objective of the RE-COVER^™ study

		Patient organisation 'Anticoagulation Europe' on the results of RE-COVER^™

		Implications of RE-COVER^™ for patients with venous thromboembolism

		Results of RE-COVER^™ in the context of RE-LY^®

		Ramifications of RE-COVER^™ for Warfarin in the treatment of venous thromboembolism

		Implications of RE-COVER^™ for clinical outcomes for venous thromboembolism

The purpose of the following information is to provide the viewer with recent scientific information. The information could be related to characteristics or properties of medicines not currently included in the approved drug profile. Please be aware that dabigatran alluded to in the following video, is approved currently only for the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and that patients and doctors should always observe current product information when taking/prescribing medications. Please note that indications can vary between countries.